Company intelligence / Profile preview

Fermiscan

Ownership: Private
Development stage: Other

Overview

Fermiscan developed and marketed a non-invasive diagnostic test using X-ray diffraction analysis of hair to detect breast cancer. The company acquired the relevant patent in 2004 and was active in commercializing this technology through the late 2000s. There are no recent reports of ongoing clinical trials or new product launches, and legal disputes have been noted regarding intellectual property.

Therapeutic areas: Oncology
Modalities: Device
Industry: Medical Imaging

Partnerships

No major pharmaceutical or biotech partnerships identified; proposed merger with Polartechnics did not complete as planned

Beyond the preview

Go deeper on Fermiscan.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fermiscan.

Explore the full profile